DLA Piper represents Commonwealth Laboratories in sale to Valeant Pharmaceuticals International
DLA Piper advised Commonwealth Laboratories in the sale of its US and Canada diagnostic testing services business to Valeant Pharmaceuticals International.
Commonwealth Laboratories is an independent organization offering tests to diagnose gastrointestinal disorders. Its breakthrough blood test, IBSchek™, is designed to help physicians quickly and reliably diagnose irritable bowel syndrome, which affects nearly 40 million Americans and an estimated 5 million Canadians.